CD34 Stem Cell Programme Sample All Participant Report. Date Issued - 06 March 2017 Closing Date - 24 March 2017 Machine Used - Facscanto II

Size: px

Start display at page:

Download "CD34 Stem Cell Programme Sample All Participant Report. Date Issued - 06 March 2017 Closing Date - 24 March 2017 Machine Used - Facscanto II"

Branden Jefferson
5 years ago
Views:

Distribution - 16176 CD3 Stem Cell Programme - 3 All Participant Report Participant ID - XXXX Date Issued - 6 March 17 Closing Date - March 17 Machine Used - Facscanto II Trial Comments This

1 Distribution CD3 Stem Cell Programme - 3 All Participant Report Participant ID - XXXX Date Issued - 6 March 17 Closing Date - March 17 Machine Used - Facscanto II Trial Comments This programme was issued to 37 participants. Comments The sample was manufactured by UK NEQAS using stabilised CD3+ samples and stabilised leucodepleted blood Absolute Values Results and Performance Please note: Performance monitoring for this programme is on absolute values only. Percentage results are shown for information purposes only. Your Results CD3 Absolute Values CD3 Absolute Values Results and Performance * Performance Status for this Performance Status Classification Over 1 Period Satisfactory Action Critical -.61 Satisfactory 1 Your Results % % % CD CD3 * Performance Status for this Performance Status Classification Over 1 Period Satisfactory Action Critical Satisfactory 1 * Limits Definitions Please note the scale below is applicable to the tables above and to the z score histograms and Shewhart control charts that follow. It is not applicable to the Cusum control charts. Absolute Percentage Report Issue Date: 9 Mar 17 ; Distribution: CD ; Version: 1.. Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 78, operating UK NEQAS for Leucocyte Immunophenotyping. Page 1 of 11

2 CD3 Stem Cell Programme - 3 Histograms of Participant s Please note denotes your result Percentage of Returns 3 1 < (%) Please note denotes your result Percentage of Returns > < > Report Issue Date: 9 Mar 17 ; Distribution: CD ; Version: 1.. Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 78, operating UK NEQAS for Leucocyte Immunophenotyping. Page of 11

3 CD3 Stem Cell Programme - 3 Shewhart Control Charts (Please note each data point represents a single sample) (%) Report Issue Date: 9 Mar 17 ; Distribution: CD ; Version: 1.. Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 78, operating UK NEQAS for Leucocyte Immunophenotyping. Page 3 of 11

4 CD3 Stem Cell Programme - 3 Cusum Control Charts (Please note each data point represents the sum of the z scores of the current sample and the two previous samples) (%) Report Issue Date: 9 Mar 17 ; Distribution: CD ; Version: 1.. Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 78, operating UK NEQAS for Leucocyte Immunophenotyping. Page of 11

5 Platform Specific Statistics (Please note only groups of > returns are displayed) CD3 Stem Cell Programme - 3 FLOW COUNT HAEMATOLOGY ANALYSER WBC TRUCOUNT Lysing Method Specific Statistics (Please note only groups of > returns are displayed) Ammonium Chloride (NHCL) Facslyse Pharmlyse Stem Kit Lyse Antibody Fluorochrome Specific Statistics (Please note only groups of > returns are displayed) PE Flow Cytometer Specific Statistics (Please note only groups of > returns are displayed) Facscalibur Facscanto II FC Navios Gating Strategy Specific Statistics (Please note only groups of > returns are displayed) BD STEM CELL ENUMERATION KIT ISHAGE STEM KIT Report Issue Date: 9 Mar 17 ; Distribution: CD ; Version: 1.. Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 78, operating UK NEQAS for Leucocyte Immunophenotyping. Page 5 of 11

6 CD3 Stem Cell Programme - 35 Distribution Participant ID - XXXX Date Issued - 6 March 17 Closing Date - March 17 Machine Used - Facscanto II Trial Comments This programme was issued to 37 participants. Comments The sample was manufactured by UK NEQAS using stabilised CD3+ samples and stabilised leucodepleted blood Absolute Values Results and Performance Please note: Performance monitoring for this programme is on absolute values only. Percentage results are shown for information purposes only. Your Results CD3 Absolute Values CD3 Absolute Values Results and Performance * Performance Status for this Performance Status Classification Over 1 Period Satisfactory Action Critical. Satisfactory 1 Your Results % % % CD CD3 * Performance Status for this Performance Status Classification Over 1 Period Satisfactory Action Critical Satisfactory 1 * Limits Definitions Please note the scale below is applicable to the tables above and to the z score histograms and Shewhart control charts that follow. It is not applicable to the Cusum control charts. Absolute Percentage Report Issue Date: 9 Mar 17 ; Distribution: CD ; Version: 1.. Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 78, operating UK NEQAS for Leucocyte Immunophenotyping. Page 6 of 11

7 CD3 Stem Cell Programme - 35 Histograms of Participant s Please note denotes your result Percentage of Returns 3 1 < (%) Please note denotes your result Percentage of Returns > < > Report Issue Date: 9 Mar 17 ; Distribution: CD ; Version: 1.. Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 78, operating UK NEQAS for Leucocyte Immunophenotyping. Page 7 of 11

8 CD3 Stem Cell Programme - 35 Shewhart Control Charts (Please note each data point represents a single sample) (%) Report Issue Date: 9 Mar 17 ; Distribution: CD ; Version: 1.. Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 78, operating UK NEQAS for Leucocyte Immunophenotyping. Page 8 of 11

9 CD3 Stem Cell Programme - 35 Cusum Control Charts (Please note each data point represents the sum of the z scores of the current sample and the two previous samples) (%) Report Issue Date: 9 Mar 17 ; Distribution: CD ; Version: 1.. Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 78, operating UK NEQAS for Leucocyte Immunophenotyping. Page 9 of 11

10 Platform Specific Statistics (Please note only groups of > returns are displayed) CD3 Stem Cell Programme - 35 FLOW COUNT HAEMATOLOGY ANALYSER WBC TRUCOUNT Lysing Method Specific Statistics (Please note only groups of > returns are displayed) Ammonium Chloride (NHCL) Facslyse Pharmlyse Stem Kit Lyse Antibody Fluorochrome Specific Statistics (Please note only groups of > returns are displayed) PE Flow Cytometer Specific Statistics (Please note only groups of > returns are displayed) Facscalibur Facscanto II FC Navios Gating Strategy Specific Statistics (Please note only groups of > returns are displayed) BD STEM CELL ENUMERATION KIT ISHAGE STEM KIT Report Issue Date: 9 Mar 17 ; Distribution: CD ; Version: 1.. Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 78, operating UK NEQAS for Leucocyte Immunophenotyping. Page 1 of 11

11 Information with respect to compliance with standards BS EN ISO/IEC 173:1.8. a) The proficiency testing provider for this programme is: UK NEQAS for Leucocyte Immunophenotyping Pegasus House, th Floor Suite 63A Glossop Road Sheffield, S1 QD United Kingdom Tel: + () , Fax: + () nicola.rose@ukneqasli.co.uk.8. b) The coordinators of UK NEQAS LI programmes are Prof David Barnett and Mr Liam Whitby..8. c) Person(s) authorizing this report: Prof David Barnett, Director or Mr Liam Whitby, Operations Manager of UK NEQAS LI.8. d) No activities in relation to this EQA exercise were subcontracted..8. g) The UK NEQAS LI Confidentiality Policy can be found in the Quality Manual which is available by contacting the UK NEQAS LI office. Participant details, their results and their performance data remain confidential unless revealed to the relevant NQAAP when a UK participant is identified as having performance issues..8. i) All EQA samples are prepared in accordance with strict Standard Operational Procedures by trained personnel proven to ensure homogeneity and stability. Where appropriate/possible EQA samples are tested prior to issue. Where the sample(s) issued is stabilised blood or platelets, pre and post stability testing will have proved sample suitability prior to issue..8. l), n), o), r) & s) Please refer to the UK NEQAS LI website at for detailed information on each programme including the scoring systems applied to assess performance (for BS EN ISO/IEC 173:1 accredited programmes only). Where a scoring system refers to the consensus result this means the result reported by the majority of participants for that trial issue. Advice on the interpretation of statistical analyses and the criteria on which performance is measured is also given. Please note that where different methods/procedures are used by different groups of participants these may be displayed within your report, but the same scoring system is applied to all participants irrespective of method/procedure used..8. m) We do not assign values against reference materials or calibrants..8. q) Details of the programme designs as authorized by The Steering Committee and Specialist Advisory Group can be found on our website at The proposed trial issue schedule for each programme is also available..8. t) If you would like to discuss the outcomes of this trial issue, please contact UK NEQAS LI using the contact details provided. Alternatively, if you are unhappy with your performance classification for this trial, please find the appeals procedure at Copy Report Issue Date: 9 Mar 17 ; Distribution: CD ; Version: 1.. Page 11 of 11 Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 78, operating UK NEQAS for Leucocyte Immunophenotyping.

JAK2 p.val617phe (V617F) Mutation Status

JAK2 p.val617phe (V617F) Mutation Status JAK2 p.val67phe (V67F) Mutation Status Distribution - 6702 Participant ID - Date Issued - 9 October 206 Closing Date - 8 November 206 Trial Comments In this trial, there were 25 participating laboratories;